Prodrugs of benzimidazol-1,2-YL amide compounds
Prodrug compounds of benzimidazol-1,2-yl amides address the solubility issues of Kv7.2/7.3 activators, enhancing their effectiveness for intravenous administration and treating conditions like status epilepticus by improving solubility and stability.
WO2026042005A1 Publication Date: 2026-02-26BIOHAVEN THERAPEUTICS LTD
6 Cites 0 Cited by
Patent Information
- Application Number
- PCT/IB2025/058358
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-08-18
- Filing Date
- 2025-08-18
- Publication Date
- 2026-02-26
AI Technical Summary
Technical Problem
Current Kv7.2/7.3 activators, such as benzimidazol-1,2-yl amides, have unsuitable aqueous solubility for intravenous, subcutaneous, or other parenteral formulations, limiting their effectiveness in treating conditions like status epilepticus.
Method used
Development of prodrug compounds of benzimidazol-1,2-yl amides with improved aqueous solubility and stability, which chemically or enzymatically release a pharmaceutically-active Kv7 activator for intravenous or parenteral administration.
Benefits of technology
The prodrugs enhance solubility and stability, enabling effective release of the active compound in plasma, thereby improving treatment efficacy for neurological disorders such as status epilepticus.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided for herein are prodrug compounds of benzimidazol-1,2-yl amide Kv7 activators. Particularly, the prodrug compounds have improved properties for stable formulation for treatment of Kv7 associated disorders, including seizure disorders. Also provided for are pharmaceutical compositions of said prodrug compounds and methods of treatment for seizure disorders including status epilepticus and others.
Need to check novelty before this filing date? Find Prior Art